Last reviewed · How we verify

Dihydrex — Competitive Intelligence Brief

Dihydrex (BENZTHIAZIDE) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: benzthiazide. Area: Cardiovascular.

marketed benzthiazide Calcium-activated potassium channel subunit alpha-1, Carbonic anhydrase 1, Carbonic anhydrase 2 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Dihydrex (BENZTHIAZIDE) — Ah Robins Inc. Dihydrex works by inhibiting the sodium-chloride cotransporter in the kidneys, reducing sodium reabsorption and increasing sodium excretion.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dihydrex TARGET BENZTHIAZIDE Ah Robins Inc marketed benzthiazide Calcium-activated potassium channel subunit alpha-1, Carbonic anhydrase 1, Carbonic anhydrase 2 1960-01-01
Bendrofluazide Bendrofluazide Boehringer Ingelheim marketed Calcium-activated potassium channel subunit alpha-1, Carbonic anhydrase 1, Carbonic anhydrase 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (benzthiazide class)

  1. Ah Robins Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dihydrex — Competitive Intelligence Brief. https://druglandscape.com/ci/benzthiazide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: